MedTrace Logo

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

NCT02948946 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2021-08-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate how well an investigational blood test performs. The study will look at the sensitivity and specificity of a blood-based multitranscriptome assay (NETest).

Conditions

  • Gastroenteropancreatic Neuroendocrine Tumor
  • Lung Neuroendocrine Neoplasm

Interventions

PROCEDURE

NETest

5 mL of blood will be drawn from participants for testing.

Sponsors & Collaborators

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Jonathan Strosberg, M.D. · H. Lee Moffitt Cancer Center and Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-09
Primary Completion
2018-08-24
Completion
2020-09-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02948946 on ClinicalTrials.gov